What do systematic reviews say?

Visual screening (oral visual inspection) by trained health workers vs No screening

• Screening programmes for the early detection and prevention of oral cancer 2013 · Cochrane All outcomes

  9 years (three cycles)
  The costs associated with the screening programme were reported after three cycles (nine years) (Subramanian 2009) (Additional Table 8). The benefit produced by a screen was 269.31 life-years saved per 100,000 for all…
  1 study
  GRADE not reported

Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment

The review found no eligible studies for this question.

• Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes
  The trials did not measure costs.
  0 studies
  No studies found

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

The review found no eligible studies for this question.

• Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
  None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
  0 studies
  No studies found

Prophylactic aciclovir (oral or intravenous) vs Prophylactic valaciclovir (oral)

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  Only one trial reported on the cost of prophylaxis for HSV (Liesveld 2002). The reported mean pharmacy costs for those randomised to receive aciclovir were $1080 compared to $320 for those initially randomised to…
  1 study · 30 participants
  GRADE not reported

Aciclovir (oral or intravenous) for treatment vs placebo

The review found no eligible studies for this question.

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
  0 studies
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found

Systemic oral acyclovir vs placebo or no treatment

The review found no eligible studies for this question.

• Acyclovir for treating primary herpetic gingivostomatitis 2008 · Cochrane All outcomes
  No data available in either included study.
  Studies not reported
  No studies found

Amifostine vs no treatment/placebo

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes

  End of RT
  Mean per-patient supportive care costs lower with amifostine (USD 4401) than control (USD 5873); P = 0.02 (Buntzel 1998 / Bennett 2001)
  1 study · 28 participants
  GRADE not reported

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

The review found no eligible studies for this question.

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  No included studies addressed direct and indirect costs to participants and health services (review-wide gap).
  0 studies
  No studies found